IDRI Licenses Vaccine Microneedles

Luke Timmerman8/31/09

The Seattle-based Infectious Disease Research Institute, a nonprofit global health research center, said today it has agreed to license technology from Israel-based NanoPass to use very short “microneedles” that cause less pain than traditional needles. The technology is supposed to stimulate the dense network of immune system cells just under the surface of the skin, which might make a number of new vaccines more protective, IDRI said in a statement. Financial terms of the agreement weren’t disclosed.

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.